Increasing Germline Genetic Testing for Patients With Cancer
Josh Peterson · with National Human Genome Research Institute (NHGRI), National Cancer Institute (NCI) · NCT07307664
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Any age listed · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 1000
- US sites recruiting
- 10
- Study start
- January 30, 2026
- Record last updated
- June 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Germline testing for hereditary cancer syndromes is underutilized across most health care settings. Using a learning health care approach, the Genomics-enabled Learning Health Systems (gLHS) network aims to evaluate the impact of a suite of implementation strategies to increase germline test ordering by oncology care teams (i.e., mainstreaming) for eligible patients with breast, pancreatic or colorectal cancer. Secondarily, the study will investigate completion of testing by eligible patients, as well as impact on overall rates of germline test ordering in patients with cancer. The network will bundle and deploy different implementation strategies across the clinical sites in three 6-month phases. A maintenance phase after the implementation periods will measure genetic testing rates without any additional implementation strategies to determine persistence of effects. The implementation strategies address clinician-level factors, and thus oncologists and their team members (e.g. advanced practice providers, nurse navigators, case managers) will be the focus of evaluating the impact of implementation strategies. Strategies that will be considered include provider education, audit and feedback reports, facilitation, peer support, and electronic health record (EHR) system optimization to support germline testing. Using the RE-AIM QuEST framework, outcomes will be assessed using mixed methods separately for each eligible cancer type. Data collection from the EHR, other relevant data sources, and qualitative provider feedback will be used to assess ordering and completion of tests and the effect of the implementation strategies on germline testing rates in oncology clinics.
Being studied: Implementation strategies
Conditions: Hereditary Pancreatic Cancer; Conditions or Focus of Study; Hereditary Breast Cancer; Hereditary Colorectal Cancer
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Oncology care team members (including, but not limited to, oncologists, advanced practice providers, nurse navigators, caring for patients with adult patients with breast cancer, pancreatic cancer or colorectal cancer.
Exclusion Criteria
- Providers not on the oncology care team
Recruiting US locations
VA Greater Los Angeles Healthcare System
Los Angeles, CA 90073
Site contact: Abby Sokoloff · abby.sokoloff@va.gov
Orlando VA Medical Center
Orlando, FL 32827
Site contact: Abby Sokoloff · abby.sokoloff@va.gov
Atlanta VA Medical Center
Decatur, GA 30033
Site contact: Abby Sokoloff · abby.sokoloff@va.gov
Northwestern Medicine
Chicago, IL 60611
Site contact: Martha Burla · martha.burla1@northwestern.edu
Indiana University School of Medicine
Indianapolis, IN 46202
Site contact: Abi Colwell · abcolwel@iu.edu
Durham VA Medical Center
Durham, NC 27705
Site contact: Abby Sokoloff · abby.sokoloff@va.gov
Salisbury VA Health Care System
Salisbury, NC 28144
Site contact: Abby Sokoloff · abby.sokoloff@va.gov
Geisinger
Danville, PA 17822
Site contact: Victoria Schlieder · schlieder@geisinger.edu
Vanderbilt University Medical Center
Nashville, TN 37203
Site contact: Kelsey Rodriguez · kelsey.rodriguez@vumc.org
University of Utah Health
Salt Lake City, UT 84112
Site contact: Kensaku Kawamoto, MD, PhD, MHS · kensaku.kawamoto@utah.edu
Study contacts (from the official record)
- Megan He, PhD · 615-875-9641 · megan.he@vumc.org
- Lynn A Seabolt, MS, RD · 615-875-7898 · lynn.a.seabolt@vumc.org
Similar studies in California
All healthy volunteers studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- Rialto, CA + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
- Location
- Lake Forest, CA + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Phase 1 Study of SBS-147 in Healthy Adults
Sparian Biosciences, Inc
- Location
- Cypress, CA
- Eligibility basics
- Ages 18–55